Exact Sciences Corporation

Exact Sciences Corporation, operating through its Exact Sciences Laboratories, LLC division and doing business as Exact, is a for-profit medical laboratory company owned by Abbott Laboratories that provides gene expression profiling and genomic oncology diagnostic testing to the Department of Veterans Affairs and Defense Health Agency as a prime contractor on full-and-open federal procurements, with all 152 recent prime awards placed on the GSA Medical Laboratory Testing and Analysis Services (FSS-621-II) Federal Supply Schedule and competing without set-aside designation.

Exact Sciences' federal work centers on Oncotype DX and Genomic Health assays—proprietary mRNA expression profiling tests that analyze cancer tumor tissue to assess recurrence risk and predict treatment responsiveness for breast, prostate, and colorectal cancers. The company also offers Cologuard colorectal cancer screening and Oncoguard liver testing. Representative recent awards include a $2.918 million delivery order from VA Strategic Acquisition Center Frederick for breast and prostate Oncotype DX testing (September 2021), a $932.881 million delivery order from Veterans Integrated Service Network 8 for gene expression testing through February 2026 (October 2022), and a $777.141 million delivery order from the Defense Health Agency for breast cancer Oncotype DX testing through February 2030 (August 2025). Smaller task orders—typically $3,000 to $50,000 per call—flow through standing blanket purchase agreements established with individual Veterans Integrated Service Networks and the Defense Health Agency.

Customer concentration is pronounced and split between VA VISNs and the Defense Health Agency. The top five funding organizations account for 90 percent of combined potential value: Veterans Integrated Service Network 12 dominates on dollars ($61.4 million across 10 awards, primarily driven by one large IDV), while VISN 15 leads on award count (36 awards, $4.1 million). The Defense Health Agency follows at 26 awards worth $6.4 million combined. A meaningful split appears between award volume and dollar share—VISN 15's 36 small calls total $4.1 million, whereas VISN 12's 10 awards (including framework agreements) reach $61.4 million, signaling reliance on both transactional and long-term vehicle work across the VA system.

All work flows through standing blanket purchase agreements and delivery orders under the Medical Laboratory Testing and Analysis Services (FSS-621-II) schedule: 196 task orders worth $36.2 million in combined potential value. Named IDVs include a $4 million single-award BPA with VISN 17 through August 2028, a $1.5 million sole-source BPA with VA Strategic Acquisition Center Frederick for breast cancer molecular testing (reflecting Exact Sciences' proprietary Oncotype DX position), a $1.071 million single-award BPA with VISN 15 through March 2027, a $690,792 sole-source BPA with VISN 6 through March 2029, and a $463,098 single-award BPA with the Defense Health Agency through August 2026. Multiple VISNs have issued framework agreements recognizing Exact Sciences as the sole source capable of delivering the Oncotype DX assay. The company has no identified subcontractors; all awards are prime delivery.

Activity has remained flat to modestly growing year over year—19 awards in 2022, 17 in 2023, 21 in 2024, and 21 in 2025, with 10 awards so far in 2026. Twenty-two awards (combined potential value $5.3 million) reach ultimate completion within the next twenty-four months and face recompete exposure. The 152 awards tracked represent $94 million in combined potential value, with $18.7 million obligated to date (20 percent of ceiling), indicating substantial unutilized contract authority across the portfolio—typical of standing laboratory services agreements with multiple task order calls per year distributed across dozens of medical facilities.

Corporate structure shows Exact Sciences Corporation as a subsidiary of Abbott Laboratories, with three named sub-divisions: Exact Sciences Thrive LLC, Exact Sciences Laboratories LLC (the performing division on federal contracts), Genomic Health Inc., and Preventiongenetics LLC. The company competes across full-and-open federal procurements with no set-aside participation, positioning itself as a specialized provider competing on capability and proprietary assay technology rather than small-business status or diversity designations.